Paris: Sanofi and Regeneron has announced that the US Food and Drug Administration (FDA) has accepted for review the ...

Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activity More than 300,000 people in the U.S. suffer from CSU that is inadequately controlled by ...

The resubmitted sBLA will include results from Study C, which evaluated biologic-naive patients with uncontrolled CSU on antihistamines.

“卵巢癌几乎被认为对现有的免疫疗法没有反应，所以对我们来说，通过阻断这种分子，IL-4，改变肿瘤的微环境，我们可以使这些难以治疗的肿瘤更容易治疗，这让我们感到非常震惊。”“这进一步证明，针对肿瘤附近，而不仅仅是癌细胞，可能是有益的。” ...

11月4日消息，一种与湿疹相关的蛋白质有助于卵巢癌细胞的存活。因此，患有这种危险肿瘤的患者可以从湿疹药物中受益。该研究结果发表在《细胞》杂志上。白罗斯理想社对此进行了报道。

The following is a summary of “Comparative safety of oral Janus kinase inhibitors versus dupilumab in patients with atopic ...

你是否曾经听说过嗜酸性食管炎（EoE）？这种慢性炎症性疾病在儿童中尤为常见，它会导致食管受损和功能障碍。想象一下，一个孩子因为吞咽困难、胃酸反流和腹部不适而无法正常进食，这对他们的成长和发育会带来多大的影响！近日，再生元（Regeneron Pharmaceuticals）与赛诺菲（Sanofi）联合宣布，其重磅疗法Dupixent（dupilumab）已获欧盟批准用于治疗1至11岁的EoE儿童患 ...

The following is a summary of “Integrative epidemiology and immuno-transcriptomics uncover a risk and potential mechanism for ...

Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria Resubmission includes new pivotal data which confirm ...

Approval based on Phase 3 data showing significantly more children aged 1 to 11 years on Dupixent achieved histological disease remission at 16 ...

(NASDAQ: REGN) and Sanofi today announced that the European Commission (EC) has approved Dupixent® (dupilumab) to treat eosinophilic esophagitis (EoE) in children as young as 1 year of age.

Dupixent® (dupilumab) Approved in the European Union as the First and Only Medicine for Young Children with Eosinophilic Esophagitis Regeneron Pharmaceuticals, Inc. Tue, Nov 5, 2024, 10:00 PM 16 ...